1. Home
  2. HELP vs NERV Comparison

HELP vs NERV Comparison

Compare HELP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$6.59

Market Cap

233.0M

Sector

Health Care

ML Signal

N/A

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.24

Market Cap

210.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HELP
NERV
Founded
N/A
2007
Country
Canada
United States
Employees
50
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.0M
210.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
HELP
NERV
Price
$6.59
$4.24
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$51.50
$10.50
AVG Volume (30 Days)
1.5M
379.3K
Earning Date
07-01-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.76
$1.76
52 Week High
$8.55
$12.46

Technical Indicators

Market Signals
Indicator
HELP
NERV
Relative Strength Index (RSI) 62.60 43.42
Support Level $5.77 $4.30
Resistance Level $7.06 $4.59
Average True Range (ATR) 0.53 0.47
MACD 0.04 -0.04
Stochastic Oscillator 70.36 21.05

Price Performance

Historical Comparison
HELP
NERV

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: